Resources from the same session
525MO - Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775
Presenter: Vicky Makker
Session: Mini Oral session 2: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
526MO - Pathological assessment of sentinel lymph node in early-stage cervical cancer: Results from the prospective SENTIX trial (CEEGOG-CX01; ENGOT-CX2)
Presenter: David Cibula
Session: Mini Oral session 2: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
527MO - Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase 3 ATHENA–MONO study
Presenter: Rebecca Kristeleit
Session: Mini Oral session 2: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
528MO - Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant?
Presenter: Gauduchon Thibault
Session: Mini Oral session 2: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
529MO - Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer
Presenter: Susana Banerjee
Session: Mini Oral session 2: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant 527MO, 528MO and 529MO
Presenter: Antonio Jose Gonzalez Martin
Session: Mini Oral session 2: Gynaecological cancers
Resources:
Slides
Webcast